UK Markets close in 1 hr

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.8700-0.4560 (-34.39%)
As of 05:01PM BST. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • P
    Peter
    Dont miss this news ...
  • R
    Rui
    From JAMA Neurology website:
    Editorial Information. The journal’s acceptance rate is 8%. The median time to first decision is 3 days, and 33 days with review. The journal's Impact Factor is 29.9, one of the highest ranking among neurology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's
  • O
    Otan
    We are very well alive here!
  • B
    Bull
    Still my favorite asset! Bullish
  • G
    Giuseppe
    Is Santhera still alive??
  • G
    Giuseppe
    Eklund needs money for his summer holidays in near future
  • A
    Aleksandar
    Did I understand well that they are waiting for FDA apporval?
  • B
    Bull
    Santhera Pharmaceuticals Holding AG, based in Pratteln, is a Swiss pharmaceutical company specializing in rare neuromuscular and pulmonary diseases. Founded in 2004, the company has been listed on the Swiss stock exchange SIX Swiss Exchange since 2006.

    https://www.santhera.com/

    Within the next 5 months the FDA will decide on the approval of Vamorolone which is a state of the art dissociative steroid for patients diagnosed with Duchenne muscular dystrophy (DMD).

    Vamorolone has a peak sales potential in the US and the EU combined of $500.000.000 per year.

    From an investors' perspective, it is basically a bet on the decision on the approval of the FDA.
    If Vamorolone gets the approval, you can expect 10x short to midterm and even more long term. If it doesn't get the approval, chances are high the company won't exist much longer.
    So all or nothing.

    The Dec. 2019 appointed CEO is a winner, check is vita. Since he took over, he delivered.
    https://ch.linkedin.com/in/darioeklund

    For me, it is so far the best investment opportunity of my life. Success chances are high.
    Check: https://www.valuationlab.com/research/

    The product will help sick children as it already does for years now as seen in various trials.
    (Participants want to stay on the drug even after completion of the study).

    https://www.santhera.com/assets/files/content/2022-03-30_SannCorpDeck_final.pdf

    Also check the latest news, e.g. https://www.santhera.com/assets/files/press-releases/2022-01-04_SperogenixLicense_e_final_220104_064153.pdf

    I highly recommend taking a closer look into this company. All information is also available in English on the homepage. 

    Bottom line
    80% Success chance, 10 bagger, ethical, love it
  • j
    jiroen
    Very promising pivotal results with Vamorolone in a rare disease indication (DMD), peak sales estimated over USD 550M. Should become standard of care (non-inferiority in efficacy, much better safety profile). Likelihood to be approved very high. Potential for further indications in other diseases.
  • C
    Christian
    With the Vamorolone data next week Santhera should start a strong move up.
    Share price control/manipulation will be over by then.
    GLTAL
  • d
    daniel
    Such a great price after phase 2 pivotal results, but looking at history, this can be dead money for a while. If somebody has any insight… thanks in advance.
  • A
    Antoni
    The price movement was a bit odd today. 20% up and then back to 1.3 per share. What’s going on? People decided to sell at such a low price and on relatively good news.
  • O
    Otan
    Haha Lars always deletes his Posts if it's not working for him.
    No bankruptcy as of now.
    Imagine FDA Approval. Going to 20$ easy
  • R
    Rui
    reveragen just confirmed that fda only asks for the existing 24 week data. There is no block to submit vamorolone right away. UK health autority just asked for imediate extended access for vamorolone (next week data will be submited). Trial for Becker dystrophy is fully funded and ready to begin on FDA funding. Age 0 to 18 DMD trial is also about to begin (authorized and fully funded)
  • d
    daniel
    Anyone have any idea of when they will publish the Phase 2b results?
  • G
    Gunnar Meister
    Any comments on SP short term? What do you guys see at market cap? I think 250M short term is realistic no? that would be about 18CHF. Thanks and Great day for patients and investors!!!
  • A
    Antoni
    Hi guys, I bought into the company 2 months ago. The pipeline looks impressive. I was wondering what are some of your expectations regarding the stock: i.e whether you think there will be a long term price raises or are you looking more into the prospect of the price going up very high on some announcment like a couple years ago when it hit over 100? Also, any thoughts on why is the stock declining? Seema to have very strong financials